Results of a phase II trial of carboplatin, pemetrexed and bevacizumab for the Treatment of never or former/light smoking patients with stage IV NSCLC

We studied first line treatment of stage IV NSCLC with carboplatin, Pemetrexed and bevacizumab. We found a median PFS of 12.6 months, ORR of 47% and median OS of 20.3 months.

from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1P9upa0
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QO1h7T
via IFTTT